Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Becton Dickinson

This article was originally published in The Gray Sheet

Executive Summary

Board of directors authorizes the repurchase of up to 10 mil. shares of the company's common stock. "We view this new share repurchase authorization as a reflection of confidence in the long-term earnings and cash flow prospects for our business. This authorization is the largest in our history and underscores our commitment to increasing shareholder value," said company Chairman, President and CEO Clateo Castellini. Franklin Lakes, New Jersey-based Becton Dickinson repurchased about 5.2 mil. shares during its 1994 fiscal year (beginning Oct. 1, 1993)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel